Loading clinical trials...
Loading clinical trials...
A Double Blind, Randomized, Placebo Controlled, Dose Escalation Phase 2a Clinical Trial for the Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers
Conditions
Interventions
RZL-012
Placebo
Locations
1
United States
Spaulding Clinical
West Bend, Wisconsin, United States
Start Date
July 25, 2017
Primary Completion Date
December 28, 2018
Completion Date
December 28, 2018
Last Updated
August 21, 2019
NCT07472881
NCT01143454
NCT07010757
NCT06989203
NCT06223555
NCT07237750
Lead Sponsor
Raziel Therapeutics Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions